ABBV STOCK HITS RECORD ALL TIME HIGH

Discussion in 'AbbVie' started by anonymous, Jun 14, 2017 at 12:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Worldwide net revenues were $7.82 billion, DOWN -1.3% on a reported basis

    The consensus estimate was for revenues of $7.7 billion.

    International Humira sales were DOWN -28%

    Because of Trumps US tax reform AbbVie paid a tax rate of 3.5 per cent on a GAAP basis.
    A disgrace and slap in the face to taxpayers. Crazy Bernie has a valid point.
     

  2. anonymous

    anonymous Guest

    We had a double beat and stocks down 0.85%. This is a back breaker. Could be part Dems Biden effect, socialism will give free medication to sick people. Medicare for all? O pipeline and Gonzalez
    raises guidance to $8.73-$8.83??
     
  3. anonymous

    anonymous Guest

    I guess Ricky is doing a good job. He never needed that degree he and Miles lied about.
     
  4. anonymous

    anonymous Guest

    duh..... Sales of the company's best-selling drug Humira fell 5.6% to $4.446 billion.
     
  5. anonymous

    anonymous Guest


    How do you sleep at night? Just curious.
     
  6. anonymous

    anonymous Guest

    Rick Gonzalez has no plan. His plan was Rova-T and Humira patent shenanigans. Rova-T crashed and Congress now preparing legislation aimed squarely at the Humira "patent estate." We are screwed. Time for a new leader who can get the stock up where it belongs so I can retire.
     
  7. anonymous

    anonymous Guest

    OOps..... stock now hitting lows last seen 2 years ago.....

    Ricky has no fuc.ing clue!!!
     
  8. anonymous

    anonymous Guest

    ABBV is just a sleeping giant. Keep your pants on!
     
  9. anonymous

    anonymous Guest

    Ian Read from Pfizer should be your new leader and CEO. You’ll see immediate results and streamlined sales force.
     
  10. anonymous

    anonymous Guest

    Sure thing, but only if you keep your diaper on Corky.
     
  11. anonymous

    anonymous Guest


    hahahaha..... looks like the market doesn't agree

    rickys latest & greatest pushes stock down to May 2017 levels....
     
  12. anonymous

    anonymous Guest

    Abbvie just bought a pile of shit!!!!! And the leaders smell worse then that pile of shit.... good fu@king luck ! If it walks like a duck , talks like a duck , shits like a duck, it’s a fu@king duck ... BS of allergan has the pipeline that he fucked up , had the Ireland address for Tax purposes they should have made him look great but didn’t and still drove the stock into the ground. Abbvie bought Allergan for Botox ( to replace Humara 2023) . So not worth the bullshit ! Brent Saunders fucks the pharma world yet again!
     
  13. anonymous

    anonymous Guest

    Not a snowballs’s chance in hell that ABBV is a sleeping giant! Just like you can’t make a whore into a house wife !
     
  14. anonymous

    anonymous Guest

    WOW, ricky must be a financial genius......
    1. AGN for the last three years has increasing net income losses. With 2018 coming in at a loss of over $5 billion. Look @ the financials, 2018 was the biggest net income loss during the last 5 years.
    2. Combine that with total assets continuing to go down the last 3 years.
    3. Don't forget shareholder equity in a downward trend the last 4 years.

    No wonder why the market is trashing rickys lack of financial judgement.
     
  15. anonymous

    anonymous Guest

    Agree, gonzalez made a good move on allergan.
     
  16. anonymous

    anonymous Guest

    Trump plans drug pricing executive order aimed at ensuring U.S. pays less than other nations

    - great to see rickys relationship with trump is working out great
     
  17. anonymous

    anonymous Guest

    Big Pharma won’t like Trump’s next move after rebate rule is abandoned 7/11/19
    • Pharma companies may be in the direct path of Trump’s next big policy push to lower drug prices after the administration abandoned a proposal that would have eliminated rebates from government drug plans.
    • Analysts say another way President Trump could make a push to lower drug prices is with a proposal announced last year that would allow Medicare to create an “international pricing index.”
     
  18. anonymous

    anonymous Guest

    AbbVie's team in Washington can handle whatever DJT throws at us. Ricky's on top of it and has everything under control.
     
  19. anonymous

    anonymous Guest

    Stock will peak to $90 and sustain that price for YEARS. Current $81.75 is good timing in relation to Allergan acquisition. Will we ever see $123 again? NOPE. Lucky I dumped 32,000 shares @ $115
    Still reluctantly holding 8000 long for sentimental reasons and in case R/D discovers a wonder drug (yeah) !! Good
    entry point to make a little dough, then bail.
     
  20. anonymous

    anonymous Guest

    $84.24 and headed north to $90